We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 PR Newswire ROCKVILLE, Md., Jan. 30, 2025 ROCKVILLE, Md., Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:...
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases PR Newswire ROCKVILLE, Md., Jan. 14, 2025 REGENXBIO to receive $110...
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 Pivotal data evaluating the safety and efficacy of the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.36 | 4.58598726115 | 7.85 | 8.63 | 7.23 | 772688 | 7.84102074 | CS |
4 | 0.08 | 0.984009840098 | 8.13 | 8.84 | 6.56 | 1114280 | 7.56982233 | CS |
12 | -3.14 | -27.6651982379 | 11.35 | 12.22 | 6.56 | 1373602 | 8.42714296 | CS |
26 | -4 | -32.76003276 | 12.21 | 13.48 | 6.56 | 882372 | 9.23680818 | CS |
52 | -3.85 | -31.9237147595 | 12.06 | 28.8 | 6.56 | 762121 | 12.48051419 | CS |
156 | -17.04 | -67.4851485149 | 25.25 | 35.73 | 6.56 | 527978 | 17.36579385 | CS |
260 | -35.83 | -81.3578564941 | 44.04 | 54.97 | 6.56 | 479360 | 23.97752501 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions